Navigation Links
Senetek PLC Reports Second Quarter 2008 Financial Results
Date:8/14/2008

Cash on Hand Totals $17.8 million at June 30

Investor Conference Call Scheduled for September 5

NAPA, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced financial results for the quarter ended June 30, 2008.

Revenue for the quarter ended June 30, 2008 was $691,000, compared with $471,000 reported in the second quarter of 2007.

Net income for the quarter ended June 30, 2008 totaled $257,000, or $0.03 per share compared to a net loss of $397,000 a loss of $0.05 per share in the second quarter of 2007. Net income for the quarter ended June 30, 2008 included other income of $1,125,000 from the previously announced settlement with Triax Aesthetics LLC and a service provider.

Cash and cash equivalents totaling $17,803,000, or $2.33 per share at June 30, 2008 represent the resources necessary to meet operating requirements for the foreseeable future.

Senetek's Board of Directors will meet on August 28, 2008. Matters to be addressed include a capital restructure to facilitate both a possible share buyback and dividend program and a Nominating Committee review of Board candidates.

Senetek will conduct a teleconference call for investors on Friday, September 5, 2008 at 9:00 a.m. Pacific, 12:00 p.m. Eastern to provide an update to include:

* Pyratine-6(TM) -- current success in U.S. physician market and Q4 2008

launch plan.

* Invicorp(R) EU -- effect of Ardana Bioscience Ltd. insolvency.

* Invicorp(R) US -- Plethora Solutions Ltd. report on status of regulatory

pathway.

* Reliaject(R) -- update on Ranbaxy's progress.

* Corporate and Product Public Relations.

The domestic dial-in number is 877-593-8638; the international dial-in number is 706-634-9240, conference ID 60464120. Mr. Frank J. Massino, Chairman and CEO, Mr. Phillip Rose, Chief Operating Officer and Mr. William F. O'Kelly, Chief Financial Officer, will participate to the call. Replay of the conference call will be available until September 12, 2008. Domestic Replay dial-in 800-642-1687, International Replay dial-in 706-645-9291, replay conference ID 60464120.

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek PLC Reports First Quarter 2008 Financial Results
2. Senetek PLC Announces Appointments of Key Personnel
3. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
4. Cadus Reports Second Quarter 2008 Results
5. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
6. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
7. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
8. Derma Sciences Reports Second Quarter 2008 Results
9. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. NeurogesX Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  The National Pharmaceutical Council (NPC) ... health policy research organization as its newest member. ... Affairs ( North America ), will serve ... "We,re pleased to have Ipsen and Dr. ... Dan Leonard . "We welcome their insights in helping ...
(Date:3/28/2017)... ... 28, 2017 , ... Currently symptomatic therapies for Parkinson’s Disease ... published in STEM CELLS suggests that human neural stem cell (hNSC) transplantation could ... more neural cells. , Strategies involving transplantation of these cells into the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, Slone Partners, ... Services. Harvill is a distinguished life sciences expert with a proven track record ... in a wide range of services related to laboratory testing and analysis for ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
Breaking Biology Technology:
(Date:3/16/2017)... 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... Used combined in one project, ... ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
Breaking Biology News(10 mins):